HUTCHMED (NASDAQ:HCM) Downgraded by StockNews.com

StockNews.com downgraded shares of HUTCHMED (NASDAQ:HCMFree Report) from a buy rating to a hold rating in a report published on Monday morning.

HUTCHMED Trading Up 0.7 %

Shares of NASDAQ HCM opened at $21.55 on Monday. The stock’s 50 day moving average price is $17.80 and its two-hundred day moving average price is $17.02. HUTCHMED has a 52-week low of $10.68 and a 52-week high of $21.92. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.60 and a current ratio of 2.72.

Hedge Funds Weigh In On HUTCHMED

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HCM. Hennion & Walsh Asset Management Inc. boosted its stake in shares of HUTCHMED by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 57,010 shares of the company’s stock worth $958,000 after acquiring an additional 1,388 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of HUTCHMED by 65.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,933 shares of the company’s stock worth $100,000 after acquiring an additional 2,340 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of HUTCHMED by 70.5% in the first quarter. Russell Investments Group Ltd. now owns 18,179 shares of the company’s stock worth $304,000 after buying an additional 7,515 shares during the period. Baillie Gifford & Co. boosted its position in shares of HUTCHMED by 7.2% in the fourth quarter. Baillie Gifford & Co. now owns 144,969 shares of the company’s stock worth $2,625,000 after buying an additional 9,694 shares during the period. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of HUTCHMED in the third quarter worth $196,000. 8.82% of the stock is owned by institutional investors.

HUTCHMED Company Profile

(Get Free Report)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.

Featured Stories

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.